| Trading Companies & Distributors Industry | Industrials Sector | Peiwen Yu CEO | OTC PINK Exchange | 29383T300 CUSIP |
| CN Country | 2 Employees | - Last Dividend | 27 Jul 2015 Last Split | - IPO Date |
Entest Group, Inc., initially founded in 2008 as Entest Biomedical, Inc., underwent a name change in February 2018, marking a new direction in its business approach. Based in Shenzhen, China, the company's current operational focus diverges from any significant operations. Instead, Entest Group, Inc. is strategically positioning itself to explore, assess, and potentially engage in business ventures. Specifically, it is open to reviewing business opportunities that could lead to mergers, acquisitions, or other forms of business combinations with companies that are operational. This strategic pivot aims to leverage potential growth opportunities by integrating or merging with existing business entities, thereby facilitating a broader business scope and operational capacity.
As of the provided information, Entest Group, Inc. does not offer traditional products or services. Instead, its focus is on the following business model:
This service entails the careful review and analysis of various business opportunities. The aim here is to identify potential companies for mergers, acquisitions, or other forms of business combinations. Entest Group, Inc. leverages its expertise to assess the viability of integrating with operational companies, seeking synergies that could lead to enhanced business growth and expansion.